Skip to content
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Clearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV

Clearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV

  • Post published:October 11, 2022
  • Post category:Press Release
Read more about the article PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial

PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial

  • Post published:October 11, 2022
  • Post category:Press Release
Read more about the article Optimi Health Announces Closing of Strategic Non-Brokered Private Placement

Optimi Health Announces Closing of Strategic Non-Brokered Private Placement

  • Post published:October 11, 2022
  • Post category:Press Release
Read more about the article Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

  • Post published:October 11, 2022
  • Post category:Press Release
Read more about the article Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022

  • Post published:October 8, 2022
  • Post category:Press Release
Read more about the article Reunion Neuroscience Inc. Announces Executive Changes

Reunion Neuroscience Inc. Announces Executive Changes

  • Post published:October 7, 2022
  • Post category:Press Release
Read more about the article Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

  • Post published:October 7, 2022
  • Post category:Press Release
Read more about the article Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

  • Post published:October 6, 2022
  • Post category:Press Release
Read more about the article COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

  • Post published:October 6, 2022
  • Post category:Press Release
Read more about the article MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference

MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference

  • Post published:October 6, 2022
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More